Background: As the proportion of older people living with HIV is increasing, it is important to study the long-term safety and efficacy of antiretroviral therapy in older individuals. B/F/TAF is a small single tablet regimen with few drug-drug interactions and a high barrier to resistance; it contains TAF resulting in less renal and bone toxicity than TDF-based regimens. We evaluated the efficacy and safety of switching participants 65 years and older to B/F/TAF from E/C/F/TAF or a TDF-containing regimen at 24 weeks. This study will follow participants for a total of 96 weeks.
Methods: Virologically suppressed(HIV-1 RNA < 50 copies/mL) participants >65 years old who were currently receiving either E/C/F/TAF or a TDF-based regimen were switched to open-label B/F/TAF. Primary endpoint was HIV-1 RNA < 50 copies/mL at Week(W) 24 as defined by the Food and Drug Administration(FDA) Snapshot algorithm.
Results: Of 86 participants, mean age was 70 years(range 65-80), 13% were female, and 99% were White; 91% (78/86) of participants were receiving E/C/F/TAF at baseline.
At W24, HIV RNA < 50 copies/mL was 98% for B/F/TAF; 2 participants had no virologic data in window and there were no virologic failures. No Grade 3-4 study-drug related adverse events(AEs) were observed. Three AEs led to premature study drug discontinuation; one was study-drug related(Table). There were no discontinuations of B/F/TAF due to a renal or bone AEs. Median change from baseline in total fasting cholesterol, LDL, HDL, triglycerides and total cholesterol:HDL were -14, -7, -3, -17 mg/dL and -0.1, respectively. Median change from baseline in eGFR was -4.5 mL/min. Median percent change in urine beta-2-microglobulin:creatinine and urine retinol binding protein:creatinine ratios were 20.8 and -15.6, respectively.
Conclusions: Through W24, high rates of virologic suppression were maintained in older participants who switched to B/F/TAF. The safety and efficacy data support the switch to B/F/TAF in virologically suppressed HIV-infected individuals aged ≥ 65 years.

Adverse EventsB/F/TAF (N=86), % (n)
Any Grades 3-4 Study Drug-Related AEs0
Grades 3 or 4 Laboratory AEs6% (5)
Any Study Drug-Related Serious AE0
AEs Leading to Study Drug Discontinuation3.5% (3)*
AEs Leading to Study Drug Discontinuation (drug-related)1% (1)?
* 1) abdominal discomfort , 2) alcohol withdrawal, 3) benzodiazepine withdrawal 
? abdominal discomfort (grade 2) 
[Adverse Events]